Healthcare / Drug Manufacturers - Specialty & GenericNZSE
$0.03
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-6.0M · quality 54.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
0/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$10M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-202.7%
↓Gross Margin
-137.8%
↓Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-4354.4%
FCF / Net income
0.27x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $85837.0 · net income $-13.7M · FCF $-3.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $85837.00 | $85837.00 | $357675.00 | $24226.00 | — |
| Net Income | $-13.7M | $-13.7M | $-6.0M | $-8.6M | $-4.7M |
| EBITDA | $-4.8M | $-4.8M | $-12.3M | $-6.7M | $-5.9M |
| EPS | -0.08 | -0.08 | -0.03 | -0.05 | -0.03 |
| Gross Margin | -137.8% | -137.8% | 5.1% | -431.0% | — |
| Operating Margin | -6115.1% | -6115.1% | -3635.0% | -37240.1% | — |
| Net Margin | -15982.3% | -15982.3% | -1666.1% | -35647.9% | — |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.01 | 0.03 | 0.05 |
| Current Ratio | 1.58 | 1.58 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.7M | $-3.7M | $-6.0M | $-7.2M | $-6.3M |
| Returns | |||||
| ROE | -202.7% | -202.7% | -29.6% | -35.7% | -15.3% |
| Valuation | |||||
| P/B | 0.83 | 0.83 | 1.41 | 2.18 | 2.11 |
| Growth & Yield | |||||
| Revenue Growth | -76.0% | -76.0% | 1376.4% | — | — |
| EPS Growth | -125.0% | -125.0% | 33.3% | -60.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+7.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.03 → -0.08
Residual
+7.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.